AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00146809
Drug: Minocyline
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00017654
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02696733
Drug: 0.9% Natrium Chloratum with a 2nd generation cephalosporin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00580034
Drug: Campath Purged Non-myeloablative ASCT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparative regimen: Begins on day -5 and consist of 4 days of daily fludarabine at 30 mg/m2/d infused over 30 minutes, cyclophosphamide 500 mg/m2/d infused over 1 hour, 5 days of Campath-1H at 20 mg/d in 250 ml of D5 normal saline or normal saline infused over 3 hours.~Patient Evaluation: Will occur 2-3 times per week by physical exam for toxicity through day 45.
Trial: NCT01231542
Drug: GSK1349572
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1349572 is an experimental drug for the treatment of HIV. GSK1349572 is in the integrase inhibitor class. It is not yet approved by the FDA.
Trial: NCT01648296
Drug: [18F]FluorbetaOx
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorine 18-labeled FluorbetaOx
Trial: NCT00926731
Drug: AZD1152
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Variable dose via a 7-day continuous infusion
Trial: NCT02594644
Drug: Aminolevulinic Acid
RxNorm normalized name: Aminolevulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levulan® Kerastick® DUSA Pharmaceuticals, Inc., Wilmington, MA
Trial: NCT01121848
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form:vials of 50 mg/5 mL or 500 mg/50mL Route of administration: IV~Dose regimen:
Trial: NCT00621556
Drug: RG1068 (Synthetic Human Secretin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose: 0.2 μg/kg of synthetic human or 18.5 µg for patients over 50 kg Route: Intravenous Frequency: Once Duration: Over 1 minute
Trial: NCT03162510
Drug: LV
RxNorm normalized name: VALVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LV 30mg twice daily from D1 to D7, every 14 days as a cycle till disease progression
Trial: NCT00822705
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control arm
Trial: NCT02359357
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00616382
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV indomethacin starting at a dose of 0.4 mg/kg given over 30 minutes, increased daily by increments of 0.2 mg/kg/dose and given at intervals of 12 hours until a maximum dose of 1 mg/kg is reached, or until a total indomethacin dose of 6 mg/kg has been given. Daily echocardiography will be performed to monitor the progress of ductal closure. Once echocardiographic evidence of a closed ductus is achieved, two additional doses indomethacin will be given 24 hours and 48 hours later, using the same dose used in the last indomethacin infusion.
Trial: NCT01599507
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIW dosing, capsule
Trial: NCT02068690
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02232581
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02704702
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02704702
Drug: Fimasartan + Rosuvastatin
RxNorm normalized name: rosuvastatin and fimasartan
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00258765
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00936533
Drug: Dysport® (Botulinumtoxin A (Btx A))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection in patients´ soles with Btx A in one foot and sodium chloride in the other, with the possibility of a second injection after 12 weeks. The drug will be given in general anaesthesia after curettage of the focal hyperkeratoses. Only the areas with focal hyperkeratoses will be injected with 50 ul per injection.The active drug Btx A (Dysport®, solution for injection) has a concentration of 100 U/ml, and the maximum dose is 300 U per foot.
Trial: NCT00936533
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo preparation without active compound, administered as the active drug.
Trial: NCT01265563
Drug: N-acetylcysteine placebo and silibin placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary Supplement: N-acetylcysteine placebo excipient and silibin placebo orally twice daily for three months
Trial: NCT01265563
Drug: N-acetylcysteine active and silibin placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary Supplement: N-acetylcysteine 600 mg orally twice daily and silibin placebo orally twice a day for three months
Trial: NCT01265563
Drug: N-acetylcysteine placebo and silibin active
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary Supplement: silibin 480 mg orally twice daily and N-acetylcysteine placebo orally twice a day for three months
Trial: NCT01265563
Drug: N-acetylcysteine active and silibin active
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary Supplement: N-acetylcysteine 600 mg orally twice daily and silibin 480 mg orally twice daily for three months
Trial: NCT01265563
Drug: N-acetylcysteine active + high-dose silibin active
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary Supplement: N-acetylcysteine 600 mg orally twice daily and silibin 960 mg orally twice daily for three months
Trial: NCT02013167
Drug: Standard of Care Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * FLAG (fludarabine, cytarabine arabinoside, and granulocyte colony-stimulating factor) ± anthracycline-based regimen (e.g. idarubicin 10 mg/m² days 1 \& 3; fludarabine 30 mg/m² days 1-5; cytarabine arabinoside 2 g/m² days 1-5). Patients \> 60 years: Idarubicin 5 mg/m² day 1 \& 3; fludarabine 20 mg/m² day 1-5; cytarabine arabinoside 1 g/m² day 1-5~* HiDAC (high-dose cytarabine arabinoside) - based regimen ≥1 g/m²/day ± anthracycline and/or in combination with other drugs such as native Escherichia coli asparaginase, polyethylene glycol linked to asparaginase (PEG-asparaginase), vinca alkaloids, steroids, etoposide or alkylating agents~* High-dose methotrexate-based regimen (HDMTX; 500 mg/m² to 3 g/m² infused up to 24 hours) in combination with native E. coli asparaginase, PEG-asparaginase, vinca alkaloids, steroids, etoposide or alkylating agents.~* Clofarabine as a single agent as recommended in the prescribing information or clofarabine-based regimens with 20 mg/m²/day for up to 5 days.
Trial: NCT04120753
Drug: OLOMAX 20/5/5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, QD
Trial: NCT04120753
Drug: OLOMAX 20/5/10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, QD
Trial: NCT05594017
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient receives a dose of saline via IV fifteen minutes prior to spatial or episodic memory task/completion.
Trial: NCT02734771
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02734771
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01345968
Drug: Ferinject 50 mg/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv administration of max. 50 ml (Dilution: 20 ml in 30 ml NaCl 0.9%) in 30 minutes
Trial: NCT01345968
Drug: NaCl 0.9%
RxNorm normalized name: DEXTROSE 5%/NACL 0.9% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv administration of max. 50 ml in 30 minutes
Trial: NCT02146638
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02142322
Drug: MODIFIED FOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified FOLFOX6 regimen consists of oxaliplatin 100 mg/m2 and FA 100 mg/m2 given as a 2 hour intravenous infusion, followed by 5-FU 2.4 g/m2 given as a continuous infusion over 46 hour, repeated every 2 weeks. Patients receive 4 cycles of neoadjuvant modified FOLFOX6 followed by curative radical surgery with D2 dissection and 4 cycles of adjuvant modified FOLFOX6.
Trial: NCT01005316
Drug: Induction Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Per standard of care guidelines for immunosuppression at each clinical site.
Trial: NCT01005316
Drug: Immunoglobulins, Intravenous
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-transplant course of intravenous immunoglobulin therapy per standard of care guidelines for immunosuppression at each clinical site.
Trial: NCT04313374
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the PCA will contain placebo
Trial: NCT00370760
Drug: oral colchicine, dexamethasone, low molecular weight heparin, 5-FU
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00370760
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02130687
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive two capsules of placebo to preserve the blinding of the study.~In a separate period, subjects will receive one capsule of placebo and one capsule of sitagliptin.
Trial: NCT03397082
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mL of sterile gel applied topically to cervix previous to clamping and paracervical blockade.
Trial: NCT00625196
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be supplied as dry powder inhaler.
Trial: NCT03214627
Drug: IV iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV iron given monthly as required - dose determined by the ACM and as agreed by the investigator
Trial: NCT00873041
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplied as matching 125 mg, 250 mg and 500 mg tablets.
Trial: NCT03214627
Drug: Erythropoiesis-Stimulating Agent (ESA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ESA given monthly as required over 6 months - dose determined by the ACM and as agreed by the investigator
Trial: NCT04616183
Drug: ERK1/2 Inhibitor LY3214996
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01007435
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Initially, patients received methotrexate 7.5 mg (3, 2.5 mg tablets) orally once a week. If a patient had swollen or tender joints, the dose was increased to 15 mg and 20 mg weekly, at the Week 4 and Week 8 visits, respectively.
Trial: NCT01007435
Drug: Placebo to methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received placebo to methotrexate orally once a week.
Trial: NCT01257230
Drug: placebo Respimat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo representing comparator
Trial: NCT00974441
Drug: Depakote®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg Extended Release Tablet
Trial: NCT01536665
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously (s.c., under the skin) once daily for 4 weeks.
Trial: NCT02209545
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 patients undergoing abdominal myomectomy operation will receive two tablets of Vitamin B6 (100mg) buccally one hour before the operation.
Trial: NCT00322023
Drug: D-serine
RxNorm normalized name: D-Serine
DrugBank: D-Serine (DB03929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-serine at following dose levels: 30 mg/kg, 60 mg/kg, and 120 mg/kg. PK/PD studies done at day 1. Medication will be administered as powder dissolved in liquid given in two divided doses daily for 4 weeks.
Trial: NCT00322023
Drug: D-serine
RxNorm normalized name: D-Serine
DrugBank: D-Serine (DB03929)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04071262
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01320553
Drug: SPARC1102 II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPARC1102 II will be administered in both eyes
Trial: NCT01320553
Drug: SPARC1102 III
RxNorm normalized name: CARDIOTOXIN III
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPARC1102 III will be administered in both eyes
Trial: NCT01320553
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle will be administered in both eyes
Trial: NCT02664649
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VKA or Antiplatelet therapy
Trial: NCT03319563
Drug: Local anesthetic-epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Bupivacaine 0.5% (Astra Zeneca) 2 mg/Kg.~* Lidocaine 5 mg/Kg.~* Epinephrine 5 mcg/ml of the total volume.~* Add normal saline to a total volume of 100 ml/10 cm of the wound length.
Trial: NCT04044599
Drug: Gynoflor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAGİNAL GYNOFLOR
Trial: NCT03831191
Drug: LY3375880
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT03831191
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT01220973
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03645525
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline
Trial: NCT04345861
Drug: hydroxychloroquine + azithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination hydroxychloroquine : 800mg(Day1) then 600 mg (Day 2 to Day 11) Azithromycin 500mg (day 1) then 250 mg (Day 2 to Day 5)
Trial: NCT05455918
Drug: TIP treatment (paclitaxel/ifosfamide/cisplatin)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel 240mg/m2/day D1 (total 240mg/m2) Ifosfamide 1.5g/m2/day D2\~5 (total 6g/m2) Cisplatin 25mg/m2/day D2\~5 (total 100mg/m2)
Trial: NCT03311139
Drug: Antithrombotic agents
RxNorm normalized name: ANTITHROMBOTIC AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelets and anticoagulants purchased 4 months before and within 7 days after the index date
Trial: NCT02185430
Drug: saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline infusion, bolus of 1.0 μg kg-1 over 10 min followed by a continuous infusion at 0.5 μg kg-1 h-1 infusion during one-lung ventilation, intravenous
Trial: NCT00189332
Drug: 852A
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00527683
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orange juice is administered twice daily in containers indistinguishable from the treatment arm.
Trial: NCT00445211
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin administered at 500units/hour while on Intra-Aortic balloon Pump (IABP).
Trial: NCT00002858
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002858
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00709293
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline will be utilized as a placebo comparator. It will be infused in the same fashion as the Thymoglobulin in the intervention arm.
Trial: NCT01951339
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg placebo once daily
Trial: NCT01951339
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg placebo once daily for three months
Trial: NCT01129713
Drug: Secretol
RxNorm normalized name: gonorrheal urethral secretion human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparing 80/80 once daily to Nexium once daily in healing erosive esophagitis.
Trial: NCT02276352
Drug: Treatment 1
RxNorm normalized name: CVS Acne Treatment 10% Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02276352
Drug: Treatment 2
RxNorm normalized name: epoch Blemish Treatment 2 % Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04457609
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Current standardized treatment for Covid-19
Trial: NCT00876850
Drug: PTK 0796
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTK 0796 100mg for injection; PTK 0796 tablet 150mg
Trial: NCT00451867
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04049266
Drug: KSI-301
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal Injection
Trial: NCT01517165
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01703208
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to omarigliptin capsule or tablet administered orally once weekly
Trial: NCT02010333
Drug: Ha44 Gel 0.74% w/w
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HA44 Gel 0.74% comprises of Abametapir as the active pharmaceutical ingredient and Benzyl Alcohol as one of the excipients.
Trial: NCT01407471
Drug: Clobetasol + Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One application 6 days a week during 4 weeks
Trial: NCT01407471
Drug: Placebo + Spironolactone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One application 6 days a week during 7 weeks
Trial: NCT01407471
Drug: Placebo + Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One application 6 days a week during 7 weeks
Trial: NCT01493102
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norepinephrine will be reduced first (0.1 microgram/kg/hour)
Trial: NCT03349216
Drug: Systemic Analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: in this group the patients will receive ketamine 1-2 mg/kg IV slow ( Bioniche,Ireland Ketamine Hydrochloride 500mg/10cc)and titrated to effect. again here the pain score will be assessed before procedure and after the procedure every 5 minutes until 30 minutes by NRS ( Numerical Rating Score)
Trial: NCT01880749
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02511483
Drug: Placebo PO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets administered with the same schedule of Propranolol tablets
Trial: NCT01335724
Drug: Diclofenac diethylamine 1.16% gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac diethylamine 1.16% gel
Trial: NCT01335724
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel
Trial: NCT04202224
Drug: Ibuprofen 400 mg and Acetaminophen 500 mg
RxNorm normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Analgesia.
Trial: NCT01069159
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The protocol of the study requires that two doses of placebo be given at the first visit, to be taken within one hour of the reactivation of the traumatic memory. Half of the subjects (33) will be randomized to receive placebo.
Trial: NCT03484507
Drug: Prednisolone Sodium Phosphate
RxNorm normalized name: Prednisolone Sodium Phosphate
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 drop 4 times daily for weeks 4-9, then 2 times daily for weeks 10-11
Trial: NCT03484507
Drug: Prednisolone Sodium Phosphate
RxNorm normalized name: Prednisolone Sodium Phosphate
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 drop 4 times daily for weeks 6-9, then 2 times daily for weeks 10-11
Trial: NCT04270682
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adult cohort patients will receive blinded 250 mg CDCA TID or placebo during the double-blind periods based upon their treatment assignment.
Trial: NCT04270682
Drug: CDCA Weight-Based Dose TID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the pediatric cohort will complete a weight-based dose titration to a tolerated dose and will maintain that tolerated dose for the remainder of the study. Pediatric cohort dosing of CDCA will not exceed an equivalent dose of 750 mg/day.
Trial: NCT00822419
Drug: non-drug cream
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: will be put on the skin
Trial: NCT00868140
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo daily
Trial: NCT02395549
Drug: 0.375% (w/w) MTC896 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.375% (w/w) MTC896 Gel
Trial: NCT02395549
Drug: 0.75% (w/w) MTC896 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75% (w/w) MTC896 Gel
Trial: NCT02395549
Drug: 1.5% (w/w) MTC896 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5% (w/w) MTC896 Gel
Trial: NCT00457821
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given q12h for 28 days each in Part 1 and Part 2 of the study